Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Ph I/II Trial of Systemic VSV-IFNβ-NIS and Pembrolizumab in Refractory NSCLC and NEC

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03647163
Recruitment Status : Recruiting
First Posted : August 27, 2018
Last Update Posted : October 15, 2021
Sponsor:
Collaborator:
Mayo Clinic
Information provided by (Responsible Party):
Vyriad, Inc.

Brief Summary:
The safety run-in portion of this study is designed to identify the optimal dose of VSV-IFNβ-NIS in combination with pembrolizumab in patients with solid tumors and follows the 3+3 design. The expansion portion will use one-sample binomial designs to assess the efficacy of the combination in patients with refractory NSCLC or NEC. The optimal dose (RP2D) determined in the dose escalation portion of the trial will be used for the expansion portion. The study has been conducted with a dose of 1.7 × 1010 as the recommended phase II dose in an expansion cohort of 10 patients with NSCLC. However, current data suggests that VSV-IFNβ-NIS doses of up to 1.7 × 1011 is safe and likely more efficacious. Thus, this study will test a second VSV-IFNβ-NIS dose level, 1.0x1011 TCID50. A safety assessment will be carried out after 3 patients are enrolled. If this dose schedule is well tolerated and virus PK are not negatively impacted, both the NSCLC and NEC expansion cohorts will open using this dose schedule. If 2 of the first 3 patients or 2 of the first 6 patients experience a DLT, the dose will be de-escalated to 5 x 1010. The safety run-in/dose escalation portion of this study is expected to require a minimum of 3 patients and a maximum of 18 patients (6 patients per dose level). The expansion portion of this study is expected to require a minimum of 10 per cohort. The NSCLC and NEC patients enrolled at the identified optimal dose in the dose escalation cohort would be included in the dose expansion cohort if they are evaluable for the primary endpoint in the expansion portion (4 dose escalation patients at the optimal dose are expected to roll over to the expansion). Therefore, the overall sample size will be a maximum of 40 patients.

Condition or disease Intervention/treatment Phase
Solid Tumor Non Small Cell Lung Cancer Neuroendocrine Carcinoma Biological: VSV-IFNβ-NIS Biological: Pembrolizumab Phase 1 Phase 2

Detailed Description:
All patients will be dosed with VSV-IFNβ-NIS on day 1. For Part A, Part B [Group 1], and Part C [Group 1] pembrolizumab will be administered on day 1 (concurrent pembrolizumab dosing). For Part A, and Parts B and C [Group 2] pembrolizumab may be administered on day 8 (delayed pembrolizumab dosing). pembrolizumab treatment will continue Q3W per the Keytruda® USPI, with efficacy evaluations after cycle 2 then every 9 weeks until PD.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 40 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Ph I/II Trial of Systemic Administration of VSV-IFNβ-NIS in Combination With Pembrolizumab, With Expansion Cohorts in Patients With Refractory NSCLC and NEC
Actual Study Start Date : April 9, 2019
Estimated Primary Completion Date : August 20, 2022
Estimated Study Completion Date : June 1, 2023


Arm Intervention/treatment
Experimental: Safety Run-in Dose Level 1
Patients with pembrolizumab refractory solid tumors will receive a single IV dose of 5e10 TCID50 VSV-IFNβ-NIS in combination with Pembrolizumab at standard labeled dose administered on day 1, then every 21 days, up to 2 years.
Biological: VSV-IFNβ-NIS
Intravenous oncolytic Vesicular stomatitis virus (VSV) expressing Interferon-beta (IFNβ) and the sodium iodide symporter (NIS)
Other Names:
  • Voyager-V1
  • VSV
  • VSV2

Biological: Pembrolizumab
Pembrolizumab

Experimental: Safety Run-in Dose Level 2
Patients with pembrolizumab refractory Neuroendocrine Carcinoma (NEC) or non small cell lung cancer (NSCLC) will receive a single IV dose of 1.0e11 TCID50 VSV-IFNβ-NIS in combination with Pembrolizumab at standard labeled dose administered on day 8, then every 21 days, up to 2 years.
Biological: VSV-IFNβ-NIS
Intravenous oncolytic Vesicular stomatitis virus (VSV) expressing Interferon-beta (IFNβ) and the sodium iodide symporter (NIS)
Other Names:
  • Voyager-V1
  • VSV
  • VSV2

Biological: Pembrolizumab
Pembrolizumab

Experimental: Expansion NEC
Patients with pembrolizumab refractory Neuroendocrine Carcinoma (NEC) will receive a single IV dose of 1.0e11 TCID50 VSV-IFNβ-NIS in combination with Pembrolizumab at standard labeled dose administered on day 8, then every 21 days, up to 2 years.
Biological: VSV-IFNβ-NIS
Intravenous oncolytic Vesicular stomatitis virus (VSV) expressing Interferon-beta (IFNβ) and the sodium iodide symporter (NIS)
Other Names:
  • Voyager-V1
  • VSV
  • VSV2

Biological: Pembrolizumab
Pembrolizumab

Experimental: Expansion NSCLC arm
Patients with pembrolizumab refractory non small cell lung cancer (NSCLC) will receive a single IV dose of 1.0e11 TCID50 VSV-IFNβ-NIS in combination with Pembrolizumab at standard labeled dose administered on day 8, then every 21 days, up to 2 years.
Biological: VSV-IFNβ-NIS
Intravenous oncolytic Vesicular stomatitis virus (VSV) expressing Interferon-beta (IFNβ) and the sodium iodide symporter (NIS)
Other Names:
  • Voyager-V1
  • VSV
  • VSV2

Biological: Pembrolizumab
Pembrolizumab




Primary Outcome Measures :
  1. Expansion arms: Overall response rate (ORR) [ Time Frame: 43 days - 6 months ]
    proportion of patients in the analysis population who have complete response (CR) or partial response (PR) based on RECIST 1.1 imaging

  2. Safety run-in arm: Number of participants with treatment related adverse events (NCI CTCAE; Version 4.03) [ Time Frame: 21 days ]
    Assessment of safety and toxicity of intravenous VSV-IFNβ-NIS in combination with pembrolizumab therapy


Secondary Outcome Measures :
  1. Overall Survival (OS) [ Time Frame: 6 months ]
    Survival time is defined as the time from registration to death due to any cause.

  2. Progression Free Survival (PFS) [ Time Frame: 6 months ]
    Progression-free survival is defined as the time from registration to the earliest date documentation of disease progression or death due to any cause

  3. Duration of response [ Time Frame: 6 months ]
    defined for all evaluable patients who have achieved an objective response as the date at which the patient's earliest best objective status is first noted to be either a CR or PR to the earliest date progression is documented.

  4. Disease Control Rate (DCR) [ Time Frame: 6 months ]
    proportion of patients in the analysis population who have complete response (CR), partial response (PR) or stable disease (SD) based on RECIST 1.1 imaging on day 43.

  5. Adverse events [ Time Frame: 6 months ]
    All eligible patients that have initiated treatment will be considered evaluable for assessing adverse event rate(s). The maximum grade for each type of adverse event will be recorded for each patient.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Histologically confirmed diagnosis of:

    • Arm 1: dose level 1 and below: Advanced and/or metastatic solid tumors for which no existing options are felt to provide clinical benefit
    • Arm 2: dose level 2: Advanced and/or metastatic NSCLC OR NEC in which radiological progression has been demonstrated during therapy with a PD-1/PD-L1 immune checkpoint inhibitor, and for which no existing options are felt to provide clinical benefit.
    • Arm 3: Advanced and/or metastatic NEC in which radiological progression has been demonstrated during therapy with a PD-1/PD-L1 immune checkpoint inhibitor, and for which no existing options are felt to provide clinical benefit.
    • Arm4: Advanced and/or metastatic NSCLC in which radiological progression has been demonstrated during therapy with a PD-1/PD-L1 immune checkpoint inhibitor, and for which no existing options are felt to provide clinical benefit.
  • Measurable disease based on RECIST 1.1. The first 3 patients in the safety run-in phase do not need measurable disease. Part C: advanced NEC (neuroendocrine carcinoma based on histopathology according to WHO criteria. Patients with small cell carcinoma, large cell neuroendocrine carcinoma, and neuroendocrine carcinoma not otherwise specified, of any primary organ are eligible in which radiological progression has been demonstrated during therapy with a PD-(L)1 immune checkpoint inhibitor, and for which no existing options are felt to provide clinical benefit.
  • Performance status of 0 or 1 on the ECOG Performance Scale.
  • Life expectancy of >3 months if not on active anti-cancer therapy
  • Willingness to provide biological samples required for the duration of the study including a fresh tumor biopsy sample (See Section 14.0).
  • Adequate organ function using predefined laboratory values obtained ≤14 days prior to registration.
  • Negative pregnancy test for female patients of childbearing potential
  • Absence of active CNS involvement. NOTE: Pre-enrollment imaging of asymptomatic patients not mandatory
  • Ability to provide written informed consent.

Exclusion Criteria:

  • Availability of and patient acceptance of curative therapy.
  • Recent or ongoing serious infection, including:

    1. Any active Grade 3 or higher (per the NCI CTCAE, version 4.03) viral, bacterial, or fungal infection within 2 weeks of registration.
    2. Known seropositivity for or active infection by the human immunodeficiency virus (HIV).
    3. Acute hepatitis B or acute hepatitis C. Patients with chronic hepatitis B or hepatitis C may be enrolled provided their liver function is adequate as per section 3.17
    4. Known history of active TB (Bacillus tuberculosis).
  • Any serious health condition, which, in the opinion of the investigator, would place the patient at undue risk from the study, including uncontrolled hypertension and/or diabetes, clinically significant pulmonary disease (e.g., chronic obstructive pulmonary disease requiring hospitalization within 3 months) or neurological disorder (e.g., seizure disorder active within 3 months)
  • Prior therapy within the following timeframe before the planned start of study treatment as follows:

    • Chemotherapy, small molecule inhibitors, radiation, interventional radiology procedure, and/or other investigational agent: ≤3 weeks or 5 half-lives, whichever is shorter
    • Other monoclonal antibodies, antibody-drug conjugates, radioimmunoconjugates, or experimental therapies: ≤4 weeks (≤3 weeks with documented disease progression)
  • New York Heart Association classification III or IV, known symptomatic coronary artery disease, or symptoms of coronary artery disease on systems review, or known cardiac arrhythmias (atrial fibrillation or SVT) (Appendix II).
  • Any known or suspected active organ-threatening autoimmune disease, such as inflammatory bowel disease, autoimmune hepatitis, lupus, or pneumonitis, with the exception of hypothyroidism and type 1 diabetes that are controlled with treatment.
  • Immunodeficiency or immunosuppression, including systemic corticosteroids at >10mg/day prednisone or equivalent within 1 week prior to planned start of study treatment
  • History of severe immune-mediated adverse reaction to immune checkpoint inhibitors.
  • Toxicities from previous therapies that have not resolved to a grade 1 or less.
  • History of non-infectious pneumonitis that required steroids, or current pneumonitis.
  • High volume disease, as assessed clinically via parameters such as radiologic impression and tumor markers or LDH.
  • Portal vein thrombosis involving more than intrahepatic portal vein branches: thrombosis of the right or left portal vein branch or the bifurcation, partial or complete obstruction of the portal vein trunk.
  • Known concurrent malignancy that is progressing or requires active treatment. EXCEPTIONS: basal cell carcinoma of the skin, squamous cell carcinoma of the skin, in-situ cervical cancer that has been treated with curative intent, prostate cancer confined to the prostate gland with Gleason score <6 or PSA <1, as well as any stage I cancer treated with curative intent or any prior cancer with a disease-free interval of ≥3 years.
  • Other concurrent anti-cancer therapy (chemotherapy, immunotherapy, radiotherapy, or any ancillary therapy considered investigational (used for a non-FDA approved indication and in the context of a research investigation)).
  • Has received a live vaccine within 30 days of planned start of study treatment. Seasonal influenza vaccines for injection are generally inactivated flu vaccines and are allowed; intranasal influenza vaccines (e.g., Flu-Mist) are live attenuated vaccines and are NOT allowed.
  • Any of the following because this study involves an investigational agent whose genotoxic, mutagenic and teratogenic effects on the developing fetus and newborn are unknown:

    • Pregnant women or women of reproductive ability who are unwilling to use highly effective contraception
    • Nursing women
    • Men who are unwilling to use a condom (even if they have undergone a prior vasectomy) while having intercourse with any woman, while taking the drug and for 4 weeks after stopping treatment.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03647163


Contacts
Layout table for location contacts
Contact: Rebecca Thomason, MBA 5072290040 rthomason@vyriad.com
Contact: Shruthi Naik, PhD snaik@vyriad.com

Locations
Layout table for location information
United States, Minnesota
Mayo Clinic Recruiting
Rochester, Minnesota, United States, 55905
Contact: Clinical Trials Referral Office    855-776-0015      
Principal Investigator: Alex Adjei, MD, PhD         
Sponsors and Collaborators
Vyriad, Inc.
Mayo Clinic
Investigators
Layout table for investigator information
Principal Investigator: Alex Adjei, MD, PhD Mayo Clinic
Layout table for additonal information
Responsible Party: Vyriad, Inc.
ClinicalTrials.gov Identifier: NCT03647163    
Other Study ID Numbers: VYR-VSV2-202
First Posted: August 27, 2018    Key Record Dates
Last Update Posted: October 15, 2021
Last Verified: October 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Vyriad, Inc.:
NSCLC
NEC
Additional relevant MeSH terms:
Layout table for MeSH terms
Carcinoma, Neuroendocrine
Neoplasms
Neuroendocrine Tumors
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Adenocarcinoma
Carcinoma
Neoplasms, Glandular and Epithelial
Neoplasms, Nerve Tissue
Pembrolizumab
Antineoplastic Agents, Immunological
Antineoplastic Agents